Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11766205 | 0.86 | CYP4F2 (0.56) | NR4A2MRGPRX4CYP4F2CYP4A11KDM5A | |
| SCHEMBL4500253 | 0.84 | RXRA (0.63) | NR4A2MRGPRX4MAOBCYP4F2CYP4A11 | |
| SCHEMBL4501976 | 0.84 | MRGPRX4 (0.55) | NR4A2MRGPRX4MAOBMAOAPARP10 | |
| SCHEMBL4505531 | 0.83 | MRGPRX4 (0.67) | NR4A2MRGPRX4MAOBCYP4F2CYP4A11 | |
| SCHEMBL2424813 | 0.80 | KMO (0.48) | NR4A2KDM5AKDM5B | |
| SCHEMBL11617562 | 0.77 | P4HTM (0.60) | NR4A2MAOBKDM5AKDM5B | |
| SCHEMBL11173291 | 0.77 | MRGPRX4 (0.63) | NR4A2MRGPRX4 | |
| SCHEMBL4512326 | 0.77 | MRGPRX4 (0.63) | MRGPRX4CYP4F2CYP4A11KDM5AKDM5B | |
| SCHEMBL4509663 | 0.76 | MRGPRX4 (0.62) | MRGPRX4CYP4F2CYP4A11KDM5AKDM5B | |
| SCHEMBL4497112 | 0.76 | MRGPRX4 (0.72) | MRGPRX4CYP4F2CYP4A11KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | NR4A2 1838/4885MRGPRX4 1550/4885MAOB 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.